NEUROSHIELD Novel small molecule attenuator of neuroinflammation in Parkinson’s Disease
- Coordinator
- Universidade Nova De Lisboa, Portugal
- Runs
- 1 June 2025 to 30 November 2026
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101188579
What the project is doing
In the project's own words, from its summary on CORDIS.
Parkinson’s disease (PD) affects 8.5 million individuals worldwide according to WHO estimates. PD remains cureless and treatments are based on administration of dopamine precursors or analogues. Neuroinflammation is a central hallmark of PD, however, no molecule is present in the market to tackle neuroinflammation in PD patients. Neuroinflammation contributes to the exacerbation of the disease, as the release of inflammatory signals leads to reduced neuronal fitness driving to neuronal death.
NEUROSHIELD will address this gap in PD treatment, to ensure an increased quality of life of PD patients, while exploiting this therapeutic market opportunity. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in PD has been considered non-effective or raised long-term usage complications due to adverse side-effects. NEUROSHIELD will employ a novel small molecule tackling neuroinflammation through a yet unexplored pathway, different mechanism to the classic NSAID COX-2 inhibitors mechanism.
We have identified a novel potent first-in-class small molecule that is a strong attenuator of neuroinflammation. NEUROSHIELD aims to explore this new safe, brain-permeable molecule, addressing neuroinflammation in Parkinson’s disease through a novel pathway
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universidade Nova De Lisboa | Lisboa | Portugal | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI